A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL
Recruiting now · Phase 1
Conditions studied: Acute Lymphoblastic Leukemia
In brief
This is a Phase 1 study to evaluate FIT-CD19-CAR-T (ARM011) safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
Key facts
- Study ID
- NCT07066397
- Run by
- TriArm Therapeutics (Taiwan) Limited
- People needed
- 12
- Starts
- 2025-07-15
- Expected to finish
- 2041-04-01
- Last updated by the study team
- 2025-07-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- National Taiwan University Hospital — Taipei, Taiwan (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.